ArticleBMC endocrine disorders2025
Elevated high-sensitivity C-reactive protein and dyslipidaemia in type 2 diabetes mellitus: implications for cardiovascular risk prediction in Nigerian patients.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Adipose Tissue Expandability as a Link Between Nutrition and Obesity-Related Metabolic Risk: Insights from Bariatric Surgery.Nutrients · 2026Review
- Carotid Intima-media Thickness is Lower after Sleeve Gastrectomy, with Concurrent Changes in Oxidized LDL and PAI-1.Obesity surgery · 2026Article
- Lipid-based atherogenic indices and their relationship with cardiovascular disease risk in an African population of type 2 diabetes mellitus patients.Cardiovascular diabetology. Endocrinology reports · 2026Article
- CRP and IL-6 as cardiovascular risk markers in diabetes.Bioinformation · 2026Article
- C-Reactive Protein-Albumin-Lymphocyte Index as a Predictor of All-Cause and Cardiovascular Mortality in Individuals With Diabetes or Prediabetes: A National Population-Based Cohort Study.International journal of endocrinology · 2026Article
- Article
- Hypertension in type 2 diabetes mellitus: prevalence, patterns, determinants and implications for cardiovascular risk prediction in a population of Nigerian patients.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Beyond blood pressure and glucose: exploring potential biochemical predictors of cardiovascular disease risk in patients with type 2 diabetes mellitus and co-morbid hypertension.BMC endocrine disorders · 2025Article
- High-sensitivity c-reactive protein and cardiovascular disease risk assessment in a population of type 2 diabetes mellitus patients.BMC cardiovascular disorders · 2025Article
- Linking high-sensitivity C-reactive protein and dyslipidemia among patients with type 2 diabetes mellitus.Bioinformation · 2025Article
- Comparison of Clotting and Inflammatory Biomarkers Between Young Hypertensive and Normotensive Adults in Ekiti State, Nigeria.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) is a leading cause of morbidity and mortality among individuals with type 2 diabetes mellitus (T2DM). Inflammation, marked by elevated high-sensitivity C-reactive protein (hs-CRP) levels, and dyslipidaemia, are critical contributors to atherosclerosis and cardiovascular risk. In Nigeria, where T2DM prevalence is rising, there is a need for more comprehensive risk prediction tools, incorporating both traditional and newer biomarkers such as hs-CRP. This study aimed to investigate the association between elevated hs-CRP levels and dyslipidaemia in Nigerian patients with T2DM and to explore the potential implications for cardiovascular risk prediction.
methodsA hospital-based cross-sectional study was conducted among 150 T2DM patients and 150 age-matched controls. Data on socio-demographics, medical history, clinical characteristics, and laboratory parameters, including lipid profiles and hs-CRP levels, were collected. The relationship between hs-CRP levels and lipid parameters was assessed using Pearson's correlation coefficient and independent t-tests.
resultsT2DM patients exhibited significantly higher hs-CRP levels (2.2 ± 1.8 mg/L vs. 1.2 ± 1.0 mg/L, p < 0.001), dyslipidaemia (p < 0.001), and blood pressure (SPB- 127.6 ± 12.4 mmHg, DBP- 77.6 ± 6.6 mmHg vs. SBP- 119.6 ± 10.8 mmHg, DBP- 72.1 ± 8.0 mmHg; p = 0.001) compared to controls. However, no significant correlation was found between hs-CRP levels and lipid parameters.
conclusionAlthough no direct association was found between elevated hs-CRP levels and dyslipidaemia, hs-CRP remains an important marker of cardiovascular risk possibly through non-lipid pathways, such as inflammation-driven endothelial dysfunction. Further research is needed to evaluate its potential role in refining cardiovascular risk assessment in the Nigerian T2DM population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.